Pivotal randomized controlled trials such as VIP-A (apremilast), VIP-S (secukinumab), VIP-U (ustekinumab), and others assessing TNF and IL-17 inhibitors have provided evidence that biologic therapy can significantly reduce vascular inflammation and modulate cardiometabolic function in moderate-to-severe psoriasis patients (25–29). This evidence concerns the gene IL17A and psoriasis.